[
  {
    "ts": null,
    "headline": "Terrible News for Pfizer Stock Investors",
    "summary": "While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results.  The past three years have been challenging for Pfizer (NYSE: PFE).  Although Pfizer has made some efforts to turn things around, they have been insufficient.",
    "url": "https://finnhub.io/api/news?id=88842df20b458aab3cb2088da7e92f3a098a01840eb1603b1c6d83f5a40b930b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748783700,
      "headline": "Terrible News for Pfizer Stock Investors",
      "id": 134928376,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results.  The past three years have been challenging for Pfizer (NYSE: PFE).  Although Pfizer has made some efforts to turn things around, they have been insufficient.",
      "url": "https://finnhub.io/api/news?id=88842df20b458aab3cb2088da7e92f3a098a01840eb1603b1c6d83f5a40b930b"
    }
  }
]